Literature DB >> 1732586

Clinical aspects of polycystic kidney disease.

E Higashihara1, Y Aso, J Shimazaki, H Ito, K Koiso, O Sakai.   

Abstract

A total of 316 patients (167 men and 149 women) with autosomal dominant polycystic kidney disease was studied retrospectively by a multi-institute group. With advancing patient age renal function decreased, and blood pressure, prevalence of liver cysts and probability of end stage renal failure increased. The probability of end stage renal failure was 39% in the patients in their sixties. Regression analysis indicated that polycystic kidney disease patients could expect to lose 1.1 ml. per minute of creatinine clearance per year, reaching a level of 10 ml. per minute, a point of end stage renal failure, by the age of 72.7 years. The better prognosis in our study than that reported previously in white patients might be due to the inclusion of more asymptomatic persons and/or milder genotypic expression of polycystic kidney disease in Japan. There was no sex difference in the prevalence of liver cysts (54.6%), pancreatic cysts (7.1%), intracranial aneurysms (8.0%) and hypertension (63.6%). The occurrence of pancreatic cysts was significantly associated with liver cysts. Our study clarifies several clinical characteristics of polycystic kidney disease in Japan.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732586     DOI: 10.1016/s0022-5347(17)37228-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

Review 1.  ADPKD: molecular characterization and quest for treatment.

Authors:  Shigeo Horie
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

2.  Linkage disequilibrium in the region of the autosomal dominant polycystic kidney disease gene (PKD1).

Authors:  A Snarey; S Thomas; M C Schneider; S E Pound; N Barton; A F Wright; S Somlo; G G Germino; P C Harris; S T Reeders
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

3.  Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan.

Authors:  Eiji Higashihara; Kikuo Nutahara; Takatsugu Okegawa; Mitsuhiro Tanbo; Hideaki Mori; Isao Miyazaki; Toshiaki Nitatori; Kuninori Kobayashi
Journal:  Clin Exp Nephrol       Date:  2014-10-29       Impact factor: 2.801

4.  Successful steroid treatment of a patient with autosomal dominant polycystic kidney disease complicated by sarcoidosis.

Authors:  Yuko Iwasa; Junko Arai; Michihiro Mitobe; Ken Tsuchiya; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2011-02-18       Impact factor: 2.801

5.  Adult polycystic kidney disease: a disorder of connective tissue?

Authors:  Anwar Ul Haque; Ambreen Moatasim
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

6.  Polycystic Kidney Disease with Renal failure Presenting as Incarcerated Inguinal Hernia in the ED.

Authors:  Eric F Silman; Bharath Chakravarthy; Federico Vaca; Mark I Langdorf
Journal:  West J Emerg Med       Date:  2009-02

7.  Multimodality Imaging in Patients with Secondary Hypertension: With a Focus on Appropriate Imaging Approaches Depending on the Etiologies.

Authors:  Hyungwoo Ahn; Eun Ju Chun; Hak Jong Lee; Sung Il Hwang; Dong-Ju Choi; In-Ho Chae; Kyung Won Lee
Journal:  Korean J Radiol       Date:  2018-02-22       Impact factor: 3.500

8.  Renal Squamous Cell Carcinoma-related Polymyositis in a Patient with Autosomal Dominant Polycystic Kidney Disease.

Authors:  Kanako Terakawa; Naoki Sawa; Hiroki Mizuno; Akinari Sekine; Noriko Hayami; Daisuke Ikuma; Masahiro Kawada; Rikako Hiramatsu; Keiichi Sumida; Masayuki Yamanouchi; Eiko Hasegawa; Tatsuya Suwabe; Junichi Hoshino; Keiichi Kinowaki; Kenichi Ohashi; Takeshi Fujii; Yoshifumi Ubara
Journal:  Intern Med       Date:  2021-04-15       Impact factor: 1.271

9.  Stone Prevalence in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis.

Authors:  Vinusha Kalatharan; Gary Grewal; Danielle M Nash; Blayne Welk; Sisira Sarma; York Pei; Amit X Garg
Journal:  Can J Kidney Health Dis       Date:  2020-07-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.